About Akorn (NASDAQ:AKRX)
Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals in a range of dosage forms, including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals and nasal sprays and otics. The Consumer Health segment consists of branded and private-label OTC products and animal health products dispensed by veterinary professionals. Its branded and private-label OTC products are focused on ophthalmics, including a dry eye treatment TheraTears Therapy for Your Eyes.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:AKRX
- CUSIP: 00972810
- Web: www.akorn.com
- Market Cap: $4.15723 billion
- Outstanding Shares: 124,916,000
- 50 Day Moving Avg: $33.08
- 200 Day Moving Avg: $33.16
- 52 Week Range: $17.61 - $34.00
Sales & Book Value:
- Trailing P/E Ratio: 33.63
- Foreward P/E Ratio: 26.63
- P/E Growth: -4.13
- Annual Revenue: $1.02 billion
- Price / Sales: 4.08
- Book Value: $7.09 per share
- Price / Book: 4.70
- EBITDA: $372.04 million
- Net Margins: 12.15%
- Return on Equity: 23.76%
- Return on Assets: 10.11%
- Debt-to-Equity Ratio: 0.92%
- Current Ratio: 5.46%
- Quick Ratio: 4.05%
- Average Volume: 2.42 million shs.
- Beta: 1.4
- Short Ratio: 4.29
Frequently Asked Questions for Akorn (NASDAQ:AKRX)
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn, Inc. (NASDAQ:AKRX) announced its quarterly earnings results on Thursday, August, 4th. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.03. The company had revenue of $280.70 million for the quarter, compared to the consensus estimate of $272.99 million. Akorn had a net margin of 12.15% and a return on equity of 23.76%. The firm's quarterly revenue was up 27.1% on a year-over-year basis. View Akorn's Earnings History.
Where is Akorn's stock going? Where will Akorn's stock price be in 2017?
11 analysts have issued twelve-month price targets for Akorn's shares. Their predictions range from $20.00 to $40.00. On average, they anticipate Akorn's stock price to reach $29.13 in the next year. View Analyst Ratings for Akorn.
What are analysts saying about Akorn stock?
Here are some recent quotes from research analysts about Akorn stock:
- 1. According to Zacks Investment Research, "Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. They also market ophthalmic surgical instruments and related products. Customers include physicians, optometrists, wholesalers, group purchasing organizations and other pharmaceutical companies. They also provide contract manufacturing services. " (8/25/2017)
- 2. Royal Bank Of Canada analysts commented, "We now see two major hurdles lifted (i) a much needed reset on 2017 EPS and (ii) greater comfort on new approvals from Decatur. From here, debate will move to whether there is enough new launch revenue to offset erosion and drive growth beyond 2017. Story is de-risked meaningfully but we are still struggling to find growth off lower base. Target down to $21... Leading into 4Q we have been concerned that Street numbers for 2017 were meaningfully too high and that new approvals were not coming from the Decatur facility. First time 2017 guidance of $1.53 to $1.72 should re-set the Street's $2.17, lowering the bar for this year, and last night's announced approvals out of Decatur assuaged concerns around facility risk. In other words, two major concerns around this stock have now been removed. We have updated our model and our 2017-19E EPS move roughly $0.30 lower but still show little growth at $1.61, $1.64 and $1.69 (but we think guidance is reasonable). The re-set reduced risk but pushes valuation to 9.3x our 2018E EBITDA which is not necessarily inexpensive against the limited growth in our model." (3/2/2017)
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include Dr. Reddy's Laboratories Ltd (RDY), Catalent (CTLT), Patheon NV (PTHN), Taro Pharmaceutical Industries (TARO), Valeant Pharmaceuticals Intl (VRX), Opko Health (OPK), BTG plc (BTG), Hikma Pharmaceuticals Plc (HIK), Horizon Pharma PLC (HZNP), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Theravance Biopharma (TBPH), Cambrex Corporation (CBM), Emergent Biosolutions (EBS), Impax Laboratories (IPXL), Innoviva (INVA), Pacira Pharmaceuticals (PCRX) and Akcea Therapeutics (AKCA).
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- John N. Kapoor Ph.D., Chairman of the Board
- Rajat Rai, Chief Executive Officer
- Duane A. Portwood, Chief Financial Officer, Executive Vice President
- Bruce Kutinsky Ph.D., Chief Operating Officer
- Joseph P. Bonaccorsi, Executive Vice President, General Counsel, Secretary
- Jonathon Kafer, Executive Vice President - Sales and Marketing
- Steven Joseph Lichter, Executive Vice President - Pharmaceutical Operations
- Randall E. Pollard, Senior Vice President, Chief Accounting Officer, Corporate Controller
- Brian Tambi, Director
- Kenneth S. Abramowitz, Independent Director
Who owns Akorn stock?
Akorn's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Longfellow Investment Management Co. LLC (0.31%), APG Asset Management N.V. (0.27%), Havens Advisors LLC (0.27%), Nationwide Fund Advisors (0.13%) and Mutual of America Capital Management LLC (0.06%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, Bruce Kutinsky, Joseph Bonaccorsi, Kenneth Abramowitz and Ronald M Johnson. View Institutional Ownership Trends for Akorn.
Who bought Akorn stock? Who is buying Akorn stock?
Akorn's stock was bought by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Havens Advisors LLC, Longfellow Investment Management Co. LLC, Nationwide Fund Advisors and Mutual of America Capital Management LLC. View Insider Buying and Selling for Akorn.
How do I buy Akorn stock?
Shares of Akorn can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akorn's stock price today?
MarketBeat Community Rating for Akorn (NASDAQ AKRX)MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Akorn stock can currently be purchased for approximately $33.29.
Consensus Ratings for Akorn (NASDAQ:AKRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Sell Ratings, 8 Hold Ratings, 1 Buy Rating|
|Consensus Rating:||Hold (Score: 1.91)|
|Consensus Price Target: ||$29.13 (12.51% downside)|Consensus Price Target History for Akorn (NASDAQ:AKRX)
Analysts' Ratings History for Akorn (NASDAQ:AKRX)
(Data available from 10/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/22/2017||Piper Jaffray Companies||Set Price Target||Hold||$34.00||N/A|
|10/3/2017||Royal Bank Of Canada||Reiterated Rating||Hold||$34.00||High|
|7/19/2017||Jefferies Group LLC||Reiterated Rating||Hold||$34.00||Low|
|4/25/2017||Gabelli||Reiterated Rating||Buy -> Hold||High|
|4/25/2017||William Blair||Downgrade||Outperform -> Market Perform||High|
|4/25/2017||Craig Hallum||Downgrade||Buy -> Hold||High|
|4/10/2017||Deutsche Bank AG||Reiterated Rating||Hold||$24.00||Low|
|3/10/2017||WallachBeth Capital||Boost Price Target||Hold -> Hold||$22.00 -> $25.00||Low|
|12/1/2016||Goldman Sachs Group, Inc. (The)||Initiated Coverage||Sell||$20.00||N/A|
|11/7/2016||Bank of America Corporation||Downgrade||Buy -> Underperform||$22.00||N/A|
|8/5/2016||J P Morgan Chase & Co||Set Price Target||Buy||$45.00||N/A|
|8/2/2016||Raymond James Financial, Inc.||Downgrade||Outperform -> Market Perform||N/A|
|8/2/2016||Citigroup Inc.||Downgrade||Market Perform||$33.80 -> $34.00||N/A|
|5/26/2016||Leerink Swann||Reiterated Rating||Hold||N/A|
|3/23/2016||Susquehanna Bancshares Inc||Lower Price Target||Neutral||$32.00 -> $30.00||N/A|
|3/22/2016||S&P Equity Research||Lower Price Target||$25.98 -> $21.97||N/A|
|3/21/2016||Nomura||Lower Price Target||Buy||$46.00 -> $42.00||N/A|
Earnings History for Akorn (NASDAQ:AKRX)Earnings History by Quarter for Akorn (NASDAQ AKRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/1/2017||Q4 2016||$0.57||$0.58||$287.91 million||$283.70 million||View||Listen|
|11/3/2016||Q316||$0.54||$0.56||$267.04 million||$284.00 million||View||Listen|
|8/4/2016||Q216||$0.55||$0.58||$272.99 million||$280.70 million||View||Listen|
|5/16/2016||Q116||$0.43||$0.54||$264.88 million||$268.35 million||View||Listen|
|2/26/2015||Q414||$0.46||$0.49||$218.87 million||$227.80 million||View||Listen|
|11/6/2014||Q314||$0.25||$0.27||$155.20 million||$132.70 million||View||Listen|
|8/5/2014||Q214||$0.18||$0.23||$145.16 million||$150.70 million||View||Listen|
|5/6/2014||Q114||$0.15||$0.16||$91.44 million||$90.60 million||View||N/A|
|3/3/2014||Q413||$0.14||$0.14||$83.37 million||$85.00 million||View||N/A|
|8/6/2013||Q2 2013||$0.13||$0.14||$75.06 million||$77.00 million||View||N/A|
|5/7/2013||Q1 2013||$0.14||$0.13||$74.07 million||$73.90 million||View||N/A|
|2/26/2013||Q4 2012||$0.12||$0.13||$69.42 million||$71.50 million||View||N/A|
|11/6/2012||Q312||$0.13||$0.12||$69.59 million||$69.60 million||View||N/A|
Earnings Estimates for Akorn (NASDAQ:AKRX)
Current Year EPS Consensus Estimate: $1 EPS
Next Year EPS Consensus Estimate: $1.25 EPS
Dividend History for Akorn (NASDAQ:AKRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Akorn (NASDAQ:AKRX)
Insider Ownership Percentage: 28.20%Insider Trades by Quarter for Akorn (NASDAQ:AKRX)
Institutional Ownership Percentage: 69.31%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/4/2017||Brian Tambi||Director||Sell||5,165||$33.37||$172,356.05|| |
|8/3/2017||Bruce Kutinsky||COO||Sell||40,000||$33.46||$1,338,400.00|| |
|8/15/2016||Kenneth Abramowitz||Director||Sell||2,691||$30.44||$81,914.04|| |
|6/14/2016||Joseph Bonaccorsi||SVP||Sell||6,500||$29.84||$193,960.00|| |
|6/10/2016||Kenneth Abramowitz||Director||Sell||14,675||$30.16||$442,598.00|| |
|6/9/2016||Bruce Kutinsky||COO||Sell||142,000||$31.12||$4,419,040.00|| |
|6/7/2016||Ronald M Johnson||Director||Sell||7,542||$31.49||$237,497.58|| |
|6/6/2016||Kenneth Abramowitz||Director||Sell||10,900||$31.37||$341,933.00|| |
|6/3/2016||Joseph Bonaccorsi||SVP||Sell||90,250||$31.23||$2,818,507.50|| |
|6/2/2016||Alan D Weinstein||Director||Sell||50,000||$30.93||$1,546,500.00|| |
|4/21/2015||Mark M Silverberg||VP||Sell||29,000||$55.00||$1,595,000.00|| |
|3/10/2015||John N Kapoor||Director||Buy||19,000||$44.26||$840,940.00|| |
|3/3/2015||Rajat Rai||CEO||Buy||5,000||$47.70||$238,500.00|| |
|2/18/2015||Joseph Bonaccorsi||Insider||Sell||40,827||$47.33||$1,932,341.91|| |
|2/10/2015||Ronald M Johnson||Director||Sell||17,173||$46.44||$797,514.12|| |
|1/26/2015||Rajat Rai||CEO||Sell||873,985||$41.89||$36,611,231.65|| |
|1/12/2015||Mark M Silverberg||VP||Sell||38,602||$41.00||$1,582,682.00|| |
|1/9/2015||Ronald M Johnson||Director||Sell||17,173||$40.46||$694,819.58|| |
|1/2/2015||Ronald M Johnson||Director||Sell||14,300||$36.12||$516,516.00|| |
|1/2/2015||Timothy A Dick||CFO||Sell||30,150||$36.03||$1,086,304.50|| |
|12/15/2014||Brian Tambi||Director||Sell||1,200||$41.86||$50,232.00|| |
|12/12/2014||Adrienne L Graves||Director||Sell||9,557||$41.09||$392,697.13|| |
|12/11/2014||John N Kapoor||Director||Sell||50,000||$41.19||$2,059,500.00|| |
|12/9/2014||John R Sabat||VP||Sell||43,173||$40.53||$1,749,801.69|| |
|12/1/2014||Timothy A Dick||CFO||Sell||30,875||$39.23||$1,211,226.25|| |
|11/3/2014||Timothy A Dick||CFO||Sell||122,222||$44.08||$5,387,545.76|| |
|10/1/2014||Timothy A Dick||CFO||Sell||122,222||$35.24||$4,307,103.28|| |
|9/12/2014||Brian Tambi||Director||Sell||13,800||$38.00||$524,400.00|| |
|9/11/2014||Joseph Bonaccorsi||Insider||Sell||116,800||$37.89||$4,425,552.00|| |
|9/8/2014||Kenneth Abramowitz||Director||Sell||4,500||$36.54||$164,430.00|| |
|9/8/2014||Rajat Rai||CEO||Sell||147,000||$36.78||$5,406,660.00|| |
|9/8/2014||Timothy A Dick||CFO||Sell||45,000||$37.61||$1,692,450.00|| |
|9/4/2014||Alan D Weinstein||Director||Sell||5,000||$38.49||$192,450.00|| |
|8/26/2014||John N Kapoor||Director||Sell||50,000||$38.99||$1,949,500.00|| |
|8/7/2014||Rajat Rai||CEO||Sell||903,659||$33.62||$30,381,015.58|| |
|6/13/2014||Brian Tambi||Director||Buy||1,000||$27.62||$27,620.00|| |
|5/16/2014||Rajat Rai||CEO||Buy||5,000||$26.76||$133,800.00|| |
|5/14/2014||Kenneth Abramowitz||Director||Sell||2,557||$26.79||$68,502.03|| |
|12/9/2013||Alan Weinstein||Director||Sell||20,000||$25.52||$510,400.00|| |
|12/3/2013||Kenneth Abramowitz||Director||Sell||5,000||$25.35||$126,750.00|| |
|12/12/2012||Alan D Weinstein||Director||Buy||30,500||$13.67||$416,935.00|| |
Headline Trends for Akorn (NASDAQ:AKRX)
Latest Headlines for Akorn (NASDAQ:AKRX)
Loading headlines, please wait.
Akorn (AKRX) Chart for Tuesday, October, 24, 2017